跳至主要内容
临床试验/NCT02143687
NCT02143687已完成4 期

Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Exercise Performance

University of Zurich1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2014年5月最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
30
试验地点
1
主要终点
6 min walk distance

研究概览

简要总结

The purpose of this study is to investigate the effect of travelling to moderate altitude and of nocturnal oxygen therapy during a stay at moderate altitude on exercise performance of patients with pulmonary hypertension or with interstitial lung disease.

详细描述

Patients with pulmonary hypertension or with interstitial lung disease living below 800 m will be invited to participate in a randomized, cross-over field trial evaluating the hypotheses that: a), exercise capacity during a 2 day sojourn at moderate altitude is reduced in comparison to low altitude; b), exercise capacity during a 2 day sojourn at moderate altitude is improved by nocturnal oxygen therapy compared to room air (sham oxygen) administered during nights at altitude. Outcomes will be assessed at low altitude (Zurich, 490 m, baseline), and during 2 study periods of 2 days each spent at moderate altitude (St. Moritz Salastrains, 2048 m), separated by a wash-out period of at least 2 weeks spent at low altitude (<800 m). The order of stays at the different altitudes and of the treatments will be randomized.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Precapillary pulmonary hypertension, or interstitial lung disease.
  • New York Heart Association class 2-
  • Residence at low altitude (<800m).

排除标准

  • Unstable or exacerbated condition
  • Very severe pulmonary hypertension or interstitial lung disease, New York Heart Association class 4
  • Requirement for oxygen therapy at low altitude residence
  • Hypoventilation
  • More than mild or unstable cardiovascular disease
  • Use of drugs that affect respiratory center drive
  • Internal, neurologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day), inability to perform 6 min walk test.
  • Previous intolerance to moderate altitude (<2600m).
  • Exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.
  • Pregnant or nursing patients

研究组 & 干预措施

Moderate altitude sojourn

Experimental

Sojourn at moderate altitude (2048 m)

干预措施: Sham oxygen (room air) (Drug)

Moderate altitude sojourn

Experimental

Sojourn at moderate altitude (2048 m)

干预措施: Moderate altitude sojourn (Behavioral)

Moderate altitude sojourn

Experimental

Sojourn at moderate altitude (2048 m)

干预措施: Low altitude sojourn (Behavioral)

Moderate altitude sojourn

Experimental

Sojourn at moderate altitude (2048 m)

干预措施: Oxygen (Drug)

Low altitude sojourn

Experimental

Sojourn at low altitude (490 m, baseline)

干预措施: Moderate altitude sojourn (Behavioral)

Low altitude sojourn

Experimental

Sojourn at low altitude (490 m, baseline)

干预措施: Low altitude sojourn (Behavioral)

Low altitude sojourn

Experimental

Sojourn at low altitude (490 m, baseline)

干预措施: Oxygen (Drug)

Low altitude sojourn

Experimental

Sojourn at low altitude (490 m, baseline)

干预措施: Sham oxygen (room air) (Drug)

Oxygen

Active Comparator

Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m

干预措施: Moderate altitude sojourn (Behavioral)

Oxygen

Active Comparator

Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m

干预措施: Low altitude sojourn (Behavioral)

Oxygen

Active Comparator

Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m

干预措施: Oxygen (Drug)

Oxygen

Active Comparator

Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m

干预措施: Sham oxygen (room air) (Drug)

Sham oxygen (room air)

Placebo Comparator

Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights

干预措施: Moderate altitude sojourn (Behavioral)

Sham oxygen (room air)

Placebo Comparator

Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights

干预措施: Low altitude sojourn (Behavioral)

Sham oxygen (room air)

Placebo Comparator

Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights

干预措施: Oxygen (Drug)

Sham oxygen (room air)

Placebo Comparator

Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights

干预措施: Sham oxygen (room air) (Drug)

结局指标

主要结局

6 min walk distance

时间窗: Day 2 at 2048 m

Difference in the distance walked in 6 min between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2028 m.

次要结局

  • 6 min walk distance(day 3 at 2048 m)
  • Spirometry(Day 2 at 2048 m)
  • Arterial blood gas analysis(Day 2 at 2048 m)
  • Perceived exertion(Day 3 at 2048 m)
  • Severe hypoxemia(Day 1 to 3 at 2048 m)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Patients With Pulmonary Hypertension or Interstitial... | 临床试验